Analyzing enGene (NASDAQ:ENGN) & OKYO Pharma (NASDAQ:OKYO)

enGene (NASDAQ:ENGN) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.

Insider and Institutional Ownership

64.2% of enGene shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 13.7% of enGene shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares enGene and OKYO Pharma”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
enGene	N/A	N/A	-$99.92 million	N/A	N/A
OKYO Pharma	N/A	N/A	-$16.83 million	N/A	N/A

Analyst Ratings

This is a summary of recent recommendations for enGene and OKYO Pharma, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
enGene	0	0	9	1	3.10
OKYO Pharma	0	0	1	0	3.00

enGene currently has a consensus target price of $30.38, suggesting a potential upside of 251.16%. OKYO Pharma has a consensus target price of $7.00, suggesting a potential upside of 585.60%. Given OKYO Pharma’s higher possible upside, analysts plainly believe OKYO Pharma is more favorable than enGene.

Risk and Volatility

enGene has a beta of -0.76, indicating that its share price is 176% less volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.11, indicating that its share price is 111% less volatile than the S&P 500.

Profitability

This table compares enGene and OKYO Pharma’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
enGene	N/A	-66.38%	-56.00%
OKYO Pharma	N/A	N/A	N/A

Summary

OKYO Pharma beats enGene on 6 of the 10 factors compared between the two stocks.

About enGene

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.